Raymond James analyst Robert Dodd downgrades Newtek Business Services (NASDAQ:NEWT) from Market Perform to Underperform.
MyMD Pharmaceuticals Announces Publication Of Phase 1 Data For Oral TNF-alpha Inhibitor MYMD-1 In Peer-Reviewed Journal Drug Research
MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and